Cargando…

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

INTRODUCTION: Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) are approved for use in metastatic non-small cell lung cancer (NSCLC). CASE PRESENTATION: Here we present a case of a African American patient with stage IIIA NSCLC treated with osimertinib in the neoadj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Caroline Y., Fares, Charlene M., Shin, Daniel Sanghoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066434/ https://www.ncbi.nlm.nih.gov/pubmed/33892800 http://dx.doi.org/10.1186/s13256-021-02748-y

Ejemplares similares

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
por: Shin, Sumin, et al.
Publicado: (2020)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
por: Hu, Yan, et al.
Publicado: (2022)

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
por: Wang, Jiangfeng, et al.
Publicado: (2021)

Effects of Neoadjuvant Therapy After the Initial Assessment of Operability in Patients with Borderline Operable and Inoperable Stage IIIA Non-small Lung Cancer
por: Pilav, Ilijaz, et al.
Publicado: (2020)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma
por: Singh, Neetu, et al.
Publicado: (2020)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy
por: Qu, Chenghao, et al.
Publicado: (2022)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Pathological complete response in an advance stage IIIB non‐small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literature
por: Soo, Chun Ian, et al.
Publicado: (2023)

The prognosis of clinical stage IIIa non‐small cell lung cancer in Taiwan
por: Cheng, Ya‐Fu, et al.
Publicado: (2023)

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study
por: Huang, Zhangfeng, et al.
Publicado: (2021)

Select octogenarians with stage IIIa non–small cell lung cancer can benefit from trimodality therapy
por: Tang, Andrew, et al.
Publicado: (2022)

Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects
por: Zhao, Xiaoliang, et al.
Publicado: (2016)

Preoperative Concurrent Radiochemotherapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer
por: Kang, Min Kyu, et al.
Publicado: (2006)

Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer
por: Shin, Sumin, et al.
Publicado: (2020)

Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I–IIIA non-small cell lung cancer: a propensity-matched analysis
por: Xi, Junjie, et al.
Publicado: (2020)

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
por: Xiong, Liwen, et al.
Publicado: (2018)

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
por: Palka, Magda, et al.
Publicado: (2017)

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
por: Montemuiño Muñiz, Sara, et al.
Publicado: (2021)

Bone metastasis after stage IIIA non-small cell lung cancer: risks and prognosis
por: de Bessa, Camila Martins, et al.
Publicado: (2022)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Outcomes of Pulmonary Resection and Mediastinal Node Dissection by Video-Assisted Thoracoscopic Surgery Following Neoadjuvant Chemoradiation Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer
por: Jeon, Yeong Jeong, et al.
Publicado: (2018)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA)
por: Bačić, Ivan, et al.
Publicado: (2018)

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
por: Eichhorn, Florian, et al.
Publicado: (2019)

Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer
por: Shen, Qian, et al.
Publicado: (2023)

Combined modality therapy in Stage IIIA non–small cell lung cancer: clarity or confusion despite the highest level of evidence?
por: Jeremic, Branislav, et al.
Publicado: (2017)

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer
por: Das, Millie, et al.
Publicado: (2023)

Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non–small-cell lung cancer: a case report
por: Liu, Yunpeng, et al.
Publicado: (2021)

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
por: Fu, Meng, et al.
Publicado: (2022)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer
por: Dumont, Delphine, et al.
Publicado: (2017)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_06chptvriieh1jk4031icsq7sp